<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DAUNOXOME - daunorubicin citrate injection, lipid complex </strong><br>Galen US Inc<br></p></div>
<h1>DaunoXome<span class="Sup">®</span><br>(daunorubicin citrate liposome injection)<br><br><span class="Bold">Rx</span> only </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-1"></a><p></p>
<h1>WARNINGS</h1>
<ol class="Arabic">
<li>Cardiac function should be monitored regularly in patients receiving DaunoXome (daunorubicin citrate liposome injection) because of the potential risk for cardiac toxicity and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Cardiac monitoring is advised especially in those patients who have received prior anthracyclines or who have pre-existing cardiac disease or who have had prior radiotherapy encompassing the heart.</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may occur. </li>
<li>DaunoXome should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents.</li>
<li>Dosage should be reduced in patients with impaired hepatic function.<span class="Bold"> (See <a href="#Section_10">DOSAGE AND ADMINISTRATION</a>)</span>
</li>
<li>A triad of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> has been reported in 13.8% of the patients (16/116) treated with DaunoXome in the Phase III clinical trial, and in 2.7% of treatment cycles (27/994). This triad generally occurs during the first five minutes of the infusion, subsides with interruption of the infusion, and generally does not recur if the infusion is then resumed at a slower rate.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DaunoXome (daunorubicin citrate liposome injection) is a sterile, pyrogen-free, preservative-free product in a single use vial for intravenous infusion.</p>
<p>
              DaunoXome contains an aqueous solution of the citrate salt of daunorubicin encapsulated within lipid <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> (liposomes) composed of a lipid bilayer of distearoylphosphatidylcholine and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (2:1 molar ratio), with a mean diameter of about 45 nm. The lipid to drug weight ratio is 18.7:1 (total lipid:daunorubicin base), equivalent to a 10:5:1 molar ratio of distearoylphosphatidylcholine:<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>:daunorubicin. Daunorubicin is an anthracycline antibiotic with antineoplastic activity, originally obtained from <span class="Italics">Streptomyces peucetius</span>. Daunorubicin has a 4-ring anthracycline moiety linked by a glycosidic bond to daunosamine, an amino sugar. Daunorubicin may also be isolated from <span class="Italics">Streptomyces coeruleorubidus</span> and has the following chemical name: (8<span class="Italics">S-cis</span>)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-<span class="Italics">lyxo</span>-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-­methoxy-5,12-naphthacenedione hydrochloride.
            </p>
<p>Daunorubicin citrate has the following chemical structure:</p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf2b4eaf-5227-42d9-af78-88d921e565f6&amp;name=image1.jpg"></p>
<p>DSPC (distearoylphosphatidylcholine) has the following chemical structure:</p>
<p><img alt="structure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf2b4eaf-5227-42d9-af78-88d921e565f6&amp;name=image2.jpg"></p>
<p>The following represents the idealized, spherical morphology of a liposome:</p>
<p><img alt="structure3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf2b4eaf-5227-42d9-af78-88d921e565f6&amp;name=image3.jpg"></p>
<p><span class="Bold">Note: Liposomal encapsulation can substantially affect a drug's functional properties relative to those of the unencapsulated drug.</span></p>
<p><span class="Bold">In addition, different liposomal drug products may vary from one another in the chemical composition and physical form of the liposomes. Such differences can substantially affect the functional properties of liposomal drug products.</span></p>
<p>Each vial contains daunorubicin citrate equivalent to 50 mg of daunorubicin base, encapsulated in liposomes consisting of 704 mg distearoylphosphatidylcholine and 168 mg <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. The liposomes encapsulating daunorubicin are dispersed in an aqueous medium containing 2,125 mg sucrose, 94 mg glycine, and 7 mg calcium chloride dihydrate in a total volume of 25 mL/vial. The pH of the dispersion is between 4.9 and 6.0. The liposome dispersion should appear red and translucent.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action </h2>
<p class="First">DaunoXome is a liposomal preparation of daunorubicin formulated to maximize the selectivity of daunorubicin for <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> <span class="Italics">in situ</span>. While in the circulation, the DaunoXome formulation helps to protect the entrapped daunorubicin from chemical and enzymatic degradation, minimizes protein binding, and generally decreases uptake by normal (non-reticuloendothelial system) tissues. The specific mechanism by which DaunoXome is able to deliver daunorubicin to <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> <span class="Italics">in situ</span> is not known. However, it is believed to be a function of increased permeability of the tumor neovasculature to some particles in the size range of DaunoXome. In animal studies, daunorubicin has been shown to accumulate in tumors to a greater extent when administered as DaunoXome than when administered as daunorubicin. Once within the tumor environment, daunorubicin is released over time enabling it to exert its antineoplastic activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">
                  Following intravenous injection of DaunoXome, plasma clearance of daunorubicin shows monoexponential decline. The pharmacokinetic parameter values for total daunorubicin following a single 40 mg/m<span class="Sup">2</span> dose of DaunoXome administered over a 30 – 60 minute period to patients with AIDS-related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> and following a single rapid intravenous, 80 mg/m<span class="Sup">2</span> dose of conventional daunorubicin to patients with disseminated solid malignancies are shown in Table I.
                </p>
<table>
<caption><span>TABLE I PHARMACOKINETIC PARAMETERS OF DAUNOXOME IN AIDS PATIENTS WITH KAPOSI'S <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">SARCOMA</span> AND REPORTED PARAMETERS FOR CONVENTIONAL DAUNORUBICIN</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Parameter (units)</th>
<th class="Lrule" align="center">
<span class="Sup">a</span>DaunoXome</th>
<th class="Lrule Rrule" align="center">
<span class="Sup">b</span>Conventional Daunorubicin</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">
<span class="Sup">a</span> N=30; <span class="Sup">b</span> N=4; <span class="Sup">c</span> Calculated
                      </td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Plasma Clearance (mL/min)</td>
<td class="Lrule" align="center">17.3 ± 6.1</td>
<td class="Lrule Rrule" align="center">
<span class="Sup">c</span>236 ± 181
                    </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Volume of Distribution (L)</td>
<td class="Lrule" align="center">6.4 ± 1.5</td>
<td class="Lrule Rrule" align="center">1006 ± 622</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Distribution Half-Life (h)</td>
<td class="Lrule" align="center">4.41 ± 2.33</td>
<td class="Lrule Rrule" align="center">0.77 ± 0.3</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Elimination Half-Life (h)</td>
<td class="Lrule" align="center">———</td>
<td class="Lrule Rrule" align="center">55.4 ± 13.7</td>
</tr>
</tbody>
</table>
<p>The plasma pharmacokinetics of DaunoXome differ significantly from the results reported for conventional daunorubicin hydrochloride. DaunoXome has a small steady-state volume of distribution of 6.4 L, (probably because it is confined to vascular fluid volume), and clearance of 17 mL/min. These differences in the volume of distribution and clearance result in a higher daunorubicin exposure (in terms of plasma AUC) from DaunoXome than with conventional daunorubicin hydrochloride. The apparent elimination half-life of DaunoXome (daunorubicin citrate liposome injection) is 4.4 hours, far shorter than that of daunorubicin, and probably represents a distribution half-life. Although preclinical biodistribution data in animals suggest that DaunoXome crosses the normal blood-brain barrier, it is unknown whether DaunoXome crosses the blood-brain barrier in humans.</p>
<p><span class="Bold">Metabolism:</span> Daunorubicinol, the major active metabolite of daunorubicin, was detected at low levels in the plasma following intravenous administration of DaunoXome.</p>
<p>
                  No formal assessments of pharmacokinetic drug–drug interactions between DaunoXome and other agents have been conducted.
                </p>
<p><span class="Bold">Special Populations:</span> The pharmacokinetics of DaunoXome have not been evaluated in women, in different ethnic groups, or in subjects with renal and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.
             </p>
<p><span class="Bold">Clinical Study </span></p>
<p>
                  In an open-label, randomized, controlled clinical study conducted at 13 centers in the U.S.A. and Canada in advanced (25 or more mucocutaneous lesions; the development of 10 or more lesions in a one month period of time; symptomatic visceral involvement; or tumor-associated <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) HIV-related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, two treatment regimens were compared as first line cytotoxic therapy: DaunoXome 40 mg/m<span class="Sup">2</span>and ABV (doxorubicin (Adriamycin<span class="Sup">®1</span>) 10 mg/m<span class="Sup">2</span>, bleomycin 15 U, and vincristine 1.0 mg). All drugs were administered intravenously every 2 weeks. Responses were assessed using the AIDS Clinical Trials Group Oncology Committee of the National Institute of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> and Infectious Diseases (ACTG) criteria (a response required at least one of any of the following for at least 28 days: a. ≥ 50% reduction in the number; b. ≥ 50% reduction in the sums of the products of the largest perpendicular diameters of bidimensionally measurable marker lesions; or c. complete flattening of ≥ 50% of all previously raised lesions). Table II summarizes the efficacy results.
                </p>
<p>1.<span class="Bold"></span> Adriamycin is a registered trademark of Pharmacia &amp; Upjohn Co., Kalamazoo, MI.
                </p>
<table>
<caption><span>TABLE II EFFICACY DATA FIRST LINE CYTOTOXIC THERAPY FOR ADVANCED KAPOSI'S <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">SARCOMA</span></span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">
                        DaunoXome<br>n=116
                      </th>
<th class="Lrule Rrule" align="center">
                        ABV<br>n=111
                      </th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">
<span class="Sup">*</span> The 95% confidence interval for difference in the response rates (ABV – DaunoXome) was (-5%, 18%).<br><span class="Sup">**</span> The hazard ratio (ABV/DaunoXome) for duration of response was 0.80, and the 95% confidence intervals were (0.44, 1.46).<br><span class="Sup">*** </span>The hazard ratio (ABV/DaunoXome) for time to progression was 0.78, and the 95% confidence intervals were (0.57, 1.07).<br><span class="Sup">****</span> The hazard ratio for mortality (ABV/DaunoXome) was 1.29, and 95% confidence intervals were (0.92, 1.79).
                      </td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Response Rate</td>
<td class="Lrule" align="center">
                        23%*
                    </td>
<td class="Lrule Rrule" align="center">30%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Duration of Response, Median</td>
<td class="Lrule" align="center">
                        110 days**
                    </td>
<td class="Lrule Rrule" align="center">113 days</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Time to Progression, Median</td>
<td class="Lrule" align="center">
                      92 days ***
                      </td>
<td class="Lrule Rrule" align="center">105 days</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Survival</td>
<td class="Lrule" align="center">
                        342 days ****
                      </td>
<td class="Lrule Rrule" align="center">291 days</td>
</tr>
</tbody>
</table>
<p>Twenty of the 33 ABV responders responded to therapy by criteria more stringent than flattening of lesions (i.e., shrinkage of lesions and/or reduction in the number of lesions). Eleven of the 27 DaunoXome responders responded to therapy by criteria other than flattening of lesions. Photographic evidence of tumor response to DaunoXome and ABV was comparable across all anatomic sites (e.g., face, oral cavity, trunk, legs, and feet).</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">DaunoXome is indicated as a first line cytotoxic therapy for advanced HIV-associated Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>. DaunoXome is not recommended in patients with less than advanced HIV-related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Therapy with DaunoXome is contraindicated in patients who have experienced a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to previous doses of DaunoXome or to any of its constituents.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">DaunoXome is intended for administration under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents.</p>
<p>The primary toxicity of DaunoXome is <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, especially of the granulocytic series, which may be severe, and associated with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and may result in <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Effects on the platelets and erythroid series are much less marked. Careful hematologic monitoring is required and since patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> are immunocompromised, patients must be observed carefully for evidence of intercurrent or <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>.
            </p>
<p>Special attention must be given to the potential cardiac toxicity of DaunoXome. Although there is no reliable means of predicting <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> induced by anthracyclines is usually associated with a decrease of the left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF). Cardiac function should be evaluated in each patient by means of a history and physical examination before each course of DaunoXome and determination of LVEF should be performed at total cumulative doses of DaunoXome of 320 mg/m<span class="Sup">2</span>, and every 160 mg/m<span class="Sup">2</span> thereafter.
            </p>
<p>Patients who have received prior therapy with anthracyclines (doxorubicin &gt; 300 mg/m<span class="Sup">2</span> or equivalent), have pre-existing cardiac disease, or have received previous radiotherapy encompassing the heart may be less "cardiac" tolerant to treatment with DaunoXome.  Therefore, monitoring of LVEF at cumulative DaunoXome doses should occur prior to therapy and every 160 mg/m<span class="Sup">2</span> of DaunoXome.
            </p>
<p>In patients with Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> has been reported in one patient at a cumulative dose of 340 mg/m<span class="Sup">2</span> of DaunoXome. In eight Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> patients, LVEF decreases were reported at cumulative doses ranging from 200 mg/m<span class="Sup">2</span> to 2100 mg/m<span class="Sup">2</span> (median dose 320 mg/m<span class="Sup">2</span>) of DaunoXome. In clinical studies in malignancies other than Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> and treated with doses of DaunoXome greater than the recommended dose of 40 mg/m<span class="Sup">2</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> has been reported at a cumulative dose as low as 200 mg/m<span class="Sup">2</span> of DaunoXome; seven patients have been reported with LVEF decreases. The proportion of patients at risk for cardiotoxicity is unknown because the denominator is uncertain since there were several instances of missing repeat cardiac evaluations.
            </p>
<p>A triad of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> has been reported in 13.8% of the patients (16/116) treated with DaunoXome in the randomized clinical trial and in 2.7% of treatment cycles (27/994). This triad generally occurs during the first five minutes of the infusion, subsides with interruption of the infusion, and generally does not recur if the infusion is then resumed at a slower rate. This combination of symptoms appears to be related to the lipid component of DaunoXome, as a similar set of signs and symptoms has been observed with other liposomal products not containing daunorubicin.
            </p>
<p>Daunorubicin has been associated with local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> at the site of drug <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>. Although no such local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> has been observed with DaunoXome, care should be taken to ensure that there is no <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of drug when DaunoXome is administered.
            </p>
<p>Dosage should be reduced in patients with impaired hepatic function. <span class="Bold">(See <a href="#Section_10">DOSAGE AND ADMINISTRATION</a>)
              </span></p>
<p><span class="Bold">Pregnancy Category D</span></p>
<p>DaunoXome can cause fetal harm when administered to a pregnant woman. DaunoXome was administered to rats on gestation days 6 through 15 at 0.3, 1.0 or 2.0 mg/kg/day, (about 1/20th, 1/6th, or 1/3rd the recommended human dose on a mg/m<span class="Sup">2</span> basis). DaunoXome produced severe maternal toxicity and embryolethality at 2.0 mg/kg/day and was embryotoxic and caused <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (<span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, incomplete ossification) at 0.3 mg/kg/day. Embryotoxicity was characterized by increased embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>, reduced numbers of litters, and reduced litter sizes.
            </p>
<p>There are no studies of DaunoXome in pregnant women. If DaunoXome is used during pregnancy, or if the patient becomes pregnant while taking DaunoXome, the patient must be warned of the potential hazard to the fetus. Patients should be advised to avoid becoming pregnant while taking DaunoXome.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_6.4"></a><a name="section-6.1"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">In the patient population studied, DaunoXome has been administered to patients receiving a variety of concomitant medications (e.g., antiretroviral agents, antiviral agents, anti-infective agents). Although interactions of DaunoXome (daunorubicin citrate liposome injection) with other drugs have not been observed, no systematic studies of interactions have been conducted.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-6.2"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">No carcinogenesis, mutagenesis, or impairment of fertility studies were conducted with DaunoXome.</p>
<p>Carcinogenesis: Carcinogenicity and mutagenicity studies have been conducted with daunorubicin, the active component of DaunoXome. A high incidence of mammary tumors was observed about 120 days after a single intravenous dose of 12.5 mg/kg daunorubicin in rats (about 2 times the human dose on a mg/m<span class="Sup">2</span> basis). Mutagenesis: Daunorubicin was mutagenic in <span class="Italics">in vitro</span> tests (Ames assay, V79 hamster cell assay), and clastogenic in <span class="Italics">in vitro</span> (CCRF-CEM human lymphoblasts) and in <span class="Italics">in vivo</span> (SCE assay in mouse bone marrow) tests. Impairment of Fertility: Daunorubicin intravenous doses of 0.25 mg/kg/day (about 8 times the human dose on a mg/m<span class="Sup">2</span> basis) in male dogs caused <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> and total <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> of spermatocytes in the seminiferous tubules.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-6.3"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Pregnancy "Category D". See <a href="#Section_5">WARNINGS</a> Section.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_6.10"></a><a name="section-6.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.12"></a><a name="section-6.5"></a><p></p>
<h2>Use in the Elderly</h2>
<p class="First">Safety and effectiveness in the elderly have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.13"></a><a name="section-6.6"></a><p></p>
<h2>Special Populations</h2>
<p class="First">Safety has not been established in patients with pre-existing hepatic or renal dysfunction.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">DaunoXome contains daunorubicin, encapsulated within a liposome. Conventional daunorubicin has acute <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> as its dose limiting side effect, with the greatest effect on the granulocytic series. In addition, daunorubicin causes <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in a significant number of patients treated. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of conventional daunorubicin can cause severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>. Chronic therapy at total doses above 300 mg/m<span class="Sup">2</span> causes a cumulative-dose-related <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.
            </p>
<p>Administered as DaunoXome, daunorubicin has substantially altered pharmacokinetics and some differences in toxicity. The most important acute toxicity of DaunoXome remains <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, principally of the granulocytic series, with much less marked effects on the platelets and erythroid series.
            </p>
<p>In an open-label, randomized, controlled clinical trial conducted in 13 centers in the U.S.A. and Canada in advanced HIV-related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, two treatment regimens were compared as first line cytotoxic therapy: DaunoXome and ABV (doxorubicin (Adriamycin<span class="Sup">®</span>), bleomycin, and vincristine). All drugs were administered intravenously every 2 weeks. The safety data presented below include all reported or observed adverse experiences, including those not considered to be drug related. Patients with advanced HIV-associated Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> are seriously ill due to their underlying <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and are receiving several concomitant medications including potentially toxic antiviral and antiretroviral agents. The contribution of the study drugs to the adverse experience profile is therefore difficult to establish.
            </p>
<p>Table III summarizes the important safety data.
            </p>
<table>
<caption><span>TABLE III SUMMARY OF IMPORTANT SAFETY DATA</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">
                  DaunoXome<br>(N = 116)<br>% of patients
              </th>
<th class="Lrule Rrule" align="center">
                ABV<br>(N = 111)<br>% of patients
                </th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">
<span class="Sup">* The denominator is uncertain since there were several instances of missing repeat cardiac evaluations.</span><br><span class="Sup">** p = 0.21</span><br><span class="Sup">*** p = &lt; 0.001</span>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">
                  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt; 1000 cells/mm<span class="Sup">3</span>)
                </td>
<td class="Lrule" align="center">36%</td>
<td class="Lrule Rrule" align="center">35%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">
                  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt; 500 cells/mm<span class="Sup">3</span>)
                </td>
<td class="Lrule" align="center">15%</td>
<td class="Lrule Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic Infections</span>/Illnesses,% of patients</td>
<td class="Lrule" align="center">40%</td>
<td class="Lrule Rrule" align="center">27%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Median time to first <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic Infections</span>/Illnesses</td>
<td class="Lrule" align="center">214 days</td>
<td class="Lrule Rrule" align="center">
                  412 days<span class="Sup">**</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">
                  Number of cases with absolute reduction in <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> of 20 – 25%<span class="Sup">*</span>
</td>
<td class="Lrule" align="center">3</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">
                  Number of cases removed from therapy due to cardiac causes<span class="Sup">*</span>
</td>
<td class="Lrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">
                  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span><br>All grades % of patients
              </td>
<td class="Lrule" align="center">8%</td>
<td class="Lrule Rrule" align="center">
                36%<span class="Sup">***</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">
                <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span><br>All grades % of patients
                </td>
<td class="Lrule" align="center">13%</td>
<td class="Lrule Rrule" align="center">
                  41%<span class="Sup">***</span>
</td>
</tr>
</tbody>
</table>
<p>
              A triad of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> was reported in 13.8% of the patients (16/116) treated with DaunoXome in the Phase III clinical trial and in 2.7% of treatment cycles (27/994). Most of the episodes were mild to moderate in severity (12% of patients and 2.5% of treatment cycles).
            </p>
<p>
              Mild <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> was reported in 6% of patients treated with DaunoXome and moderate <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> in 2% of patients. Mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> was reported in 35% of DaunoXome patients, moderate <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in 16% of patients and severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in 3% of patients. For patients treated with DaunoXome, mild <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> was reported in 10%, moderate in 10%, and severe in 3% of patients. Although grade 3 – 4 <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">injection site inflammation</span> was reported in 2 patients treated with DaunoXome, no instances of local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> were observed with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.
            </p>
<p>
              Table IV is a listing of all the mild-moderate and severe adverse events reported on both treatment arms in Protocol 103-09 in ≥ 5% of DaunoXome patients.
            </p>
<table>
<caption><span>TABLE IV ADVERSE EXPERIENCES: PROTOCOL 103-09</span></caption>
<col align="left" valign="top" width="24%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Botrule Lrule" align="center" colspan="2">
                  DaunoXome<br>(N = 116)
                </th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">
                  ABV<br>(N = 111)
                </th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">
                  Mild<br>Moderate
                </th>
<th class="Lrule" align="center">Severe</th>
<th class="Lrule" align="center">
                  Mild<br>Moderate
                </th>
<th class="Lrule Rrule" align="center">Severe</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule" align="center">51%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">45%</td>
<td class="Lrule Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule" align="center">43%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule" align="center">44%</td>
<td class="Lrule Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule" align="center">42%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule" align="center">49%</td>
<td class="Lrule Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">34%</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule" align="center">29%</td>
<td class="Lrule Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Lrule" align="center">26%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">19%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule" align="center">23%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">17%</td>
<td class="Lrule Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="center">22%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">23%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></td>
<td class="Lrule" align="center">21%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">19%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Lrule" align="center">20%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">23%</td>
<td class="Lrule Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule" align="center">21%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">26%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">20%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">26%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td class="Lrule" align="center">19%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">23%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Lrule" align="center">16%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">8%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td class="Lrule" align="center">12%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">12%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Lrule" align="center">12%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">38%%</td>
<td class="Lrule Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Lrule" align="center">12%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">8%</td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">11%</td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">8%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Lrule" align="center">8%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">36%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="center">8%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Lrule" align="center">8%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">18%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">12%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">14%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">14%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td class="Lrule" align="center" valign="top">5%</td>
<td class="Lrule" align="center" valign="top">0%</td>
<td class="Lrule" align="center" valign="top">5%</td>
<td class="Lrule Rrule" align="center" valign="top">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Tenesmus</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
</tbody>
</table>
<p>
              The following adverse events were reported in ≤ 5% of patients treated with DaunoXome, tabulated by body system.
            </p>
<p><span class="Bold">Body As A Whole:</span> <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">Injection site inflammation</span>
            </p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flushes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. In other follow-up clinical trials of DaunoXome (daunorubicin citrate liposome injection) use in treatment of Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> or other malignancies, the following serious cardiac events were reported: <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="318450" conceptname="Cardiac tamponade">pericardial tamponade</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> (see <a href="#Section_5">WARNINGS</a> section).
            </p>
<p><span class="Bold">Digestive:</span> <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gingival bleeding</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries</span>
            </p>
<p><span class="Bold">Hemic and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>
            </p>
<p><span class="Bold">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>
            </p>
<p><span class="Bold">Nervous:</span> <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>
            </p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, pulmonary infiltration, increased <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>
            </p>
<p><span class="Bold">Skin:</span> <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">Folliculitis</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>
            </p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>
            </p>
<p><span class="Bold">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>
            </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The symptoms of acute overdosage are increased severities of the observed dose-limiting toxicities of therapeutic doses of DaunoXome, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> (especially <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DaunoXome should be administered intravenously over a 60 minute period at a dose of 40 mg/m<span class="Sup">2</span>, with doses repeated every two weeks. Blood counts should be repeated prior to each dose, and therapy withheld if the absolute granulocyte count is less than 750 cells/mm<span class="Sup">3</span>. Treatment should be continued until there is evidence of progressive disease (e.g., based on best response achieved: new visceral sites of involvement, or progression of visceral disease; development of 10 or more new, cutaneous lesions or a 25% increase in the number of lesions compared to baseline; a change in the character of 25% or more of all previously counted flat lesions to raised; increase in surface area of the indicator lesions), or until other intercurrent complications of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> preclude continuation of therapy.</p>
<p><span class="Bold">Patients with Impaired Hepatic and Renal Function </span></p>
<p>Limited clinical experience exists in treating hepatically and renally impaired patients with DaunoXome.</p>
<p>Therefore, based on experience with daunorubicin HCl, it is recommended that the dosage of DaunoXome be reduced if the bilirubin or creatinine is elevated as follows: Serum bilirubin 1.2 to 3 mg/dL, give ¾ the normal dose; serum bilirubin or creatinine &gt; 3 mg/dL, give ½ the normal dose.<br>Do not mix DaunoXome with other drugs.</p>
<p><span class="Bold">Preparation Of Solution</span></p>
<p>DaunoXome should be diluted 1:1 with 5% Dextrose Injection (D5W) before administration. Each vial of DaunoXome contains daunorubicin citrate equivalent to 50 mg daunorubicin base, at a concentration of 2 mg/mL. The recommended concentration after dilution is 1 mg daunorubicin/mL of solution.</p>
<p><span class="Bold">Use aseptic technique.</span></p>
<p>Aseptic technique must be strictly observed in all handling, since no preservative or bacteriostatic agent is present in DaunoXome or in the materials recommended for dilution.</p>
<p>Withdraw the calculated volume of DaunoXome from the vial into a sterile syringe, and transfer it into a sterile infusion bag containing an equivalent amount of D5W. Administer diluted DaunoXome immediately. If not used immediately, diluted DaunoXome should be refrigerated at 2°– 8 °C (36°– 46°F) for a maximum of 6 hours.</p>
<p><span class="Bold">Caution: The <span class="Underline">only</span> fluid which may be mixed with DaunoXome is D5W; DaunoXome must not be mixed with saline, bacteriostatic agents such as benzyl alcohol, or any other solution.</span></p>
<p>Do not use an in-line filter for the intravenous infusion of DaunoXome.</p>
<p><span class="Bold">All parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. DaunoXome is a translucent dispersion of liposomes that scatters light to some degree. Do not use DaunoXome if it appears opaque, or has precipitate or foreign matter present.</span></p>
<p>Procedures for proper handling and disposal of anticancer drugs should be followed.<span class="Sup">1–8</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">DaunoXome is a translucent, red, liposomal dispersion supplied in single use vials, each sealed with a synthetic rubber stopper and aluminum sealing ring with a plastic cap. DaunoXome provides daunorubicin citrate equivalent to 50 mg of daunorubicin base, at a concentration of 2 mg/mL.</p>
<p>DaunoXome is supplied under NDC 10885-001-01 for a single unit pack.</p>
<p><span class="Bold">Storage</span></p>
<p>Store DaunoXome in a refrigerator, 2°–8°C (36°–46°F). Do not freeze. Protect from light.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_14"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburg, Pa: Oncology Nursing Society; 1999:32–41.</li>
<li>Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. Washington, DC: Division of Safety, Clinical Center Pharmacy Department and Cancer Nursing Services, National Institutes of Health; 1992. US Dept of Health and Human Services, Public Health Service Publication NIH 92-2621.</li>
<li>AMA Council on Scientific Affairs. Guidelines for Handling Parenteral Antineoplastics. <span class="Italics">JAMA</span>. 1985;253:1590–1591.</li>
<li>National Study Commission on Cytotoxic Exposure - Recommendations for Handling Cytotoxic Agents. 1987. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.</li>
<li>Clinical Oncological Society of Australia. Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. <span class="Italics">Med J Australia.</span> 1983;1:426–428.</li>
<li>Jones RB, Frank R, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> T. Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. CA-<span class="Italics">A Cancer J for Clin</span>. 1983;33:258–263.</li>
<li>American Society of Hospital Pharmacists. ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. <span class="Italics">Am J Hosp Pharm</span>. 1990;47:1033–1049.</li>
<li>Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines). <span class="Italics">Am J Health-Syst Pharm</span>. 1996;53:1669–1685.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_8"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured for<br>Galen US Inc. <br>25 Fretz Road<br>Souderton<br>PA 18964</p>
<p><span class="Bold">For medical information about DaunoXome (daw-nuh-zome), call 1-800-280-5708</span></p>
<p>DaunoXome is a registered trademark of Galen Limited.</p>
<br>Copyright 2011, Galen Limited.
            <p>All rights reserved.</p>
<p> Rev. December 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-13"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 10885-001-01</span></p>
<p><span class="Bold">DaunoXome<span class="Sup">®</span></span></p>
<p><span class="Bold">(daunorubicin citrate liposome injection)</span></p>
<p><span class="Bold">50 mg/vial (2 mg/mL)</span></p>
<p><span class="Bold">FOR INTRAVENOUS INFUSION ONLY</span></p>
<p><span class="Bold">Note: Liposomal Formulation -See Package Insert Prior To Use.</span></p>
<p><span class="Bold">Rx only</span></p>
<br><div class="Figure"><img alt="50 mg/vial (2 mg/mL)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf2b4eaf-5227-42d9-af78-88d921e565f6&amp;name=daunoxome2mg-ml.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DAUNOXOME 		
					</strong><br><span class="contentTableReg">daunorubicin citrate injection, lipid complex</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10885-001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DAUNORUBICIN CITRATE</strong> (DAUNORUBICIN) </td>
<td class="formItem">DAUNORUBICIN</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">CHOLESTEROL</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DISTEAROYLPHOSPHATIDYLCHOLINE, DL-</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10885-001-01</td>
<td class="formItem">25 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050704</td>
<td class="formItem">02/13/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Galen US Inc
							(029491194)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Gilead Sciences Inc</td>
<td class="formItem"></td>
<td class="formItem">941715849</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>79e3adbb-6c31-4a1c-8200-1ae6ec96aa2a</div>
<div>Set id: bf2b4eaf-5227-42d9-af78-88d921e565f6</div>
<div>Version: 3</div>
<div>Effective Time: 20120518</div>
</div>
</div> <div class="DistributorName">Galen US Inc</div></p>
</body></html>
